Clinical Trial Update: Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating vorinostat (SAHA) with bevacizumab and daily temozolomide for recurrent malignant gliomas, including glioblastoma, has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Temozolomide (Temozolomide)
• Zolinza (vorinostat) (vorinostat)

Snippet

Sponsor: Katy Peters | Conditions: Brain Tumor, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-06-24